Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions

Clinical Chemistry

Volumn 44, Issue 12, 1998, Pages 2462-2470

  Gion, Massimo ^a,b   Mione, Riccardo ^a   Barioli, Paola ^a   Barichello, Mario ^a   Zattoni, Filiberto ^c,d   Prayer Galetti, Tommaso ^c   Plebani, Mario ^e   Aimo, Giuseppe ^f   Terrone, Carlo ^g   Manferrari, Fabio ^h,i   Madeddu, Giuseppe ^h   Caberlotto, Livio ^j   Fandella, Andrea ^j   Pianon, Carlo ^k   Vianello, Luisa ^k  

^a Venice Regional Hospital   (Italy)

^b Ospedale Civile   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Regional Hospital   (Italy)

^e Central Laboratory   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY OF SASSARI   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j Regional Hospital   (Italy)

^k Regional Hospital   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 7844247583     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.12.2462     Document Type: Article

References (36)

1. Zanetti R, Crosignani P, ROSSO S. Cancer in Italy. Incidence data from cancer 1988-1992 registries. Rome, Italy: II Pensiero Scientifico Editore, 1997:390 pp.
2. Mettlin C, Lee F, Drago J, Murphy GP, the Investigators of the American Cancer Society National Prostate Cancer Detection Project. Finding on the detection of early prostate cancer in 2425 men. Cancer 1991;67:2949-58.
3. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
4. Cooner WH, Mosley BR, Rutherford CL, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-54.
5. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
6. Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen-critical issues for the practicing physician. Mayo Clin Proc 1994; 69:59-68.
7. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142: 1011-7.
8. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, et al. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 1994;74:3146-58.
9. Lilja H, Christensson A, Dahlén U, Matikainen M, Nilsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with α-1-antichymotrypsin. Clin Chem 1991;37:1618-25.
10. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1- antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
11. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett ATK, et al. Serum prostate specific antigen complexed to alfa 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
12. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
13. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson P, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154: 1090-5.
14. Filella X, Alcover J, Molina R, Gimenez N, Rodriguez A, Jo J, et al. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer 1995;63:780-4.
15. Chen Y, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518-24.
16. Prestagiacomo AF, Lilja H, Pettersson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996;56:350-4.
17. van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl 1996;7:30-4.
18. Morgan TO, Mcleod DG, Leifer ES, Moul JW, Murphy GP. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate 1996;7:58-63.
19. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, et al. Analytical performance and clinical validity of two free prostatespecific antigen assays compared. Clin Chem 1996;42:1026-33.
20. Correale M, Pagliarulo A, Donatuti G, Sturdá F, Capobianco AML, Stigliani V, et al. Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Int J Biol Markers 1996;11:24-8.
21. Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer 1997;79:90-8.
22. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79:104-9.
23. Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSym system. Urology 1997;49:19-27.
24. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen PSA for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996;48:55-61.
25. Elgamal AAA, Cornillie FJ, van Poppel HP, van de Voorde WM, McCabe R, Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 1996;156:1042-9.
26. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-7.
27. Van Iersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate Suppl 1996;7:48-57.
28. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate. J Urol 1998;159:5-12.
29. Ahddux AG, Teutsch SM, Shaffer PA, Dunet DO. Prevention effectiveness. A guide to decision analysis and economic evaluation. New York: Oxford University Press, 1992:246 pp.
30. Vashi AR, Oesterling JE. Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Mayo Clin Proc 1997;72:337-44.
31. Zucchelli GC, Pilo A, Chiesa MR, Cohen R, Bizollon CA. Analytical performance of free PSA immunoassays: results from an interlaboratory survey. Clin Chem 1997;43:2426-9.
32. Wener MH, Daum PR, Brawer MK. Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995;41:1730-7.
33. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with a1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
34. Woodrum D, French C. Stability of free PSA in serum. Clin Chem 1996;42:256-61.
35. Tarle M, Kraljic I. Free and total serum PSA in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Anticancer Res 1997;17:1531-4.
36. Watson RA, Tang DB. The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 1980;303:497-9.